Microsoft Word - DSU Degarelix FINAL sent to NICE - Phase response - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-06-17 10:44:39 GnRH agonists Degarelix Prostate cancer Goserelin Antiandrogen Triptorelin Buserelin Ferring Pharmaceuticals Gonadotropin-releasing hormone agonist Prostate Management of prostate cancer Androgen deprivation therapy		Microsoft Word - DSU Degarelix FINAL sent to NICE Add to Reading List Source URL: www.nicedsu.org.uk Download Document from Source Website File Size: 194,14 KB Share Document on Facebook

	The Company Driven by research and a passion for science, Ferring Pharmaceuticals is a biopharmaceutical company dedicated to the development of innovative treatments that make a real difference in people’s lives all o DocID: 1qPia - View Document
	Microsoft Word - DSU Degarelix FINAL sent to NICE DocID: 1oZJA - View Document
	tax incentives setting-up, establishing and developing businesses © Alain Herzog / EPFL © Ferring pharmaceuticals DocID: 1nSb7 - View Document
	Ferring Pharmaceuticals Inc. Educational Grant Applicant Working Guide 2014 DocID: 1gNzV - View Document
	Fertility Preservation Program Hearing you have cancer is overwhelming. For females of child bearing age, future fertility may be of concern. Fertility preservation treatments can help. Ferring Pharmaceuticals and Walgre DocID: 175lz - View Document